You have successfully sign out
Loading...
Diffusion Pharmaceuticals Inc.
DFFN
Company Description
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Â
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
4.40USD
0.41Â ( 10.28%)Market Closed (as of Aug 16, 20:00 EDT)
Relative Strenght
36
Volume Buzz
631%
Earning Acce
Yes
Dist 52w H.
69%
